A Placebo Controlled, Randomized, Parallel Cohort, Safety And Tolerability Study Of 2 Dose Levels Of Liposomal Amikacin For Inhalation (Arikace) In Patients With Bronchiectasis Complicated By Chronic Infection Due To Pseudomonas Aeruginosa
Phase of Trial: Phase I/II
Latest Information Update: 05 Oct 2016
At a glance
- Drugs Amikacin (Primary)
- Indications Bronchiectasis; Pseudomonal infections
- Focus Adverse reactions
- Sponsors Transave
- 14 Sep 2009 Positive phase II results presented at ERS 2009, according to a Transave media release.
- 11 Sep 2009 Interim results have been presented at the 19th Annual Congress of the European Respiratory Society.
- 17 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.